MedTrace Logo

Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

NCT03088254 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2018-07-06

No results posted yet for this study

Summary

To evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with dyslipidemia with hypertension.

Conditions

  • Dyslipidemia With Hypertension

Interventions

DRUG

Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)

Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks

DRUG

Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)

Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks

DRUG

Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)

Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks

Sponsors & Collaborators

  • Jeil Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-20
Primary Completion
2017-07-31
Completion
2017-12-04

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03088254 on ClinicalTrials.gov